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Testicular cancer is the most common malignancy of men aged 15–40. Metastatic spread classically begins with involvement of
the retroperitoneal lymph nodes, with metastases to the liver, lung, bone, and brain representing advancing disease. Treatment is
based on pathologic analysis of the excised testicle and presence of elevated tumor markers. We report a case of a 34-year-old male
presenting with back pain who was found to have a right renal mass with tumor extension into the inferior vena cava. Subsequent
biopsy was consistent with seminoma. We review this rare case and discuss the literature regarding its diagnosis and management.
1. Introduction
Testicular cancers are the most commonmalignancy for men
aged 15–40 [1]. Of these, seminoma accounts for approxi-
mately 45% of tumors, and patients typically present with
a testicular mass. When metastatic, the primary landing
sites are the retroperitoneal lymph nodes. Metastases to the
liver, lung, bone, and brain represent more advanced disease.
Treatment is based on pathologic analysis of the excised
testicle, evidence of metastasis to the retroperitoneal lymph
nodes or elsewhere, and the presence or absence of elevated
tumor markers. Treatment for seminoma may involve sys-
temic chemotherapy, radiation, and/or extirpative surgery.
2. Case Presentation
A 34-year-old Latino man was referred to clinic with a diag-
nosis of a renal mass with inferior vena caval thrombus. This
was initially found after he reported a one-month history of
back pain. He denied any hematuria, pain, weight loss, lower
extremity edema, and his physical exam was unremarkable.
An MRI showed an 8 cm renal mass with tumor thrombus
extending into the IVC, below the diaphragm (Figure 1).
Additionally, he had bilateral retroperitoneal lymphad-
enopathy and a left supraclavicular mass. His LDH was ele-
vated at 408 and his AFP and HCG were both within normal
limits. Given his age, elevated tumor markers, and extensive
adenopathy concerning for testicular cancer, he underwent
a scrotal ultrasound, which demonstrated a hypoechoic left
testicular lesion (Figure 2).
The patient initially underwent a biopsy of the supraclav-
icular lymph node, but the histology showed only necrosis
and was noncontributory. He then underwent a biopsy of the
renal mass as well as a subsequent left inguinal orchiectomy.
Histologically, the renal biopsy supported the diagnosis of
metastatic seminoma, showing homogeneous,medium-sized
tumor cells that were loosely organized in nests, surrounded
by fibrous stroma with a lymphocytic infiltrate, with no
renal cortex or medulla seen. No granulomas were identified.
Immunohistochemical staining showed that the tumor cells
were positive for SALL4, vimentin, c-Kit, and OCT4 and
negative for CD30, desmin, SMA, and cytokeratins AE1/AE3.
The orchiectomy specimen grossly showed unremarkable
brown spongy parenchyma, with an ill-defined, tan-yellow
shiny area 1.3 cm in greatest dimension and confined to
the testes. Histologically, the testis excision showed marked
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Figure 1: MRI showing right renal mass with IVC thrombus (red arrows) and retroperitoneal lymphadenopathy (green arrows).
Figure 2: Testicular ultrasound showing hypoechoic lesion in left
testis.
fibrosis consistent with regressed seminoma.No viable tumor
was found (Figure 3).
The patient was subsequently referred to medical oncol-
ogy for chemotherapy and further treatment. An IVC
filter was placed cephalad to the thrombus and he was
started on bleomycin, etoposide, and cisplatin (BEP) sys-
temic chemotherapy with side effects of watery diarrhea
and fatigue. During treatment with BEP, he was admitted
to the hospital due to development of neutropenic fever,
severe mouth pain, and genital lesions consistent with HSV
infection. After 3 cycles of BEP, he developed pulmonary
toxicity and bleomycin was discontinued for the fourth
cycle. He underwent a CT scan six months after presen-
tation showing substantial interval decrease in the size of
bilateral retroperitoneal, pelvic, and left lower cervical lym-
phadenopathy. Marked interval decrease in the size of the
IVC thrombus was also noted. These changes were thought
to be consistent with necrosis secondary to chemotherapeu-
tic effect on the lymphadenopathy. New scattered ground
glass airspace opacities in the bilateral mid- and lower
lungs were also seen, consistent with his bleomycin induced
pulmonary toxicity. The patient received two additional
cycles of EP, after which the patient underwent a PET
scan (now seven months postpresentation). This PET scan
showed mild retroperitoneal enhancement consistent with
resolving necrosis. Repeat CT scan obtained eight months
after presentation and treatment showed no change in the
partially calcified lymphnodes in the retroperitoneumand an
unchanged stable eccentric thrombus of the IVC (Figure 4).
There was no evidence of metastasis or recurrence. The
patient will be followed radiographically for recurrence every
three to six months for five years as per NCCN Guidelines
for stage III intermediate-risk seminoma. If the patient is
found to have a recurrence, his multidisciplinary team will
evaluate the need for additional chemotherapy, radiation, or
retroperitoneal lymph node dissection.
3. Discussion
Testicular cancer is the most common cancer in males
between the ages of 15 and 40 [1]. Across all ages, there will
be an estimated 8,820 new cases and 380 deaths in 2014 [2].
95% of these are germ cell tumors, including seminoma and
nonseminomatous germ cell tumors (NSGCT). Metastatic
spread of these tumors typically occurs via retroperitoneal
lymphatics, and most common sites include retroperitoneal
lymph nodes, lungs, liver, brain, and bone. Retroperitoneal
tumors diagnosed as seminoma are virtually always metas-
tases and will usually have evidence of a corresponding pri-
mary intratesticular malignancy. However, extensive fibrosis
can make the pathologic diagnosis difficult, and complete
regression of the tumor can occasionally be seen [3].
Grossly, intratesticular seminoma presents as a cream or
tan-colored nodular mass. Microscopically, confluent sheets
of cells are seen with clear or eosinophilic cytoplasm. The
sheets are classically divided by fibrous bands containing a
prominent lymphocytic infiltrate. In both primary tumors
andmetastases, granulomas are a classic feature. Syncytiotro-
phoblast can be seen and should not be overinterpreted as
evidence of choriocarcinoma. Seminomas typically stain pos-
itively for placental alkaline phosphatase (PLAP), CD117/c-
Kit, OCT3/4, SALL4, vimentin, and D2-40. In contrast, they
are negative for CD30, desmin, SMA, and pan-cytokeratin.
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Figure 3: (a) Renal biopsy showing classic seminoma histology. H&E, original magnification 200x. (b) Testis showing fibrosis consistent with
regressed seminoma. H&E, original magnification 20x.
Figure 4: CT scan obtained 8 months after presentation status postchemotherapy showing reduction in the soft tissue stranding and
thickening of the right kidney (green arrows) as well as stability of the retroperitoneal lymph nodes (red arrows).
These immunostains are useful in differentiating subtypes
of germ cell tumors and identifying minor components, as
mixed germ cell tumors are common.
Ultrasonography remains the standard imaging modality
for testicular malignancy, and CT with oral and intravenous
contrast is preferred for diagnosis of retroperitoneal lym-
phadenopathy. While this study focuses predominately on
seminomatous testicular tumors, the NCCN recommends
postdiagnostic abdomen and pelvis CT scan, with or without
chest imaging, for both seminoma andNSGCT. Additionally,
bone scan or brain MRI should be performed as clinically
indicated [4]. Tumor markers (LDH, HCG, and AFP) should
be collected postorchiectomy for cancer staging. Following
orchiectomy, seminoma can be further treated with radi-
ation or medical therapy. NCCN guidelines recommend
etoposide and cisplatin, with or without bleomycin, as the
initial chemotherapy for metastatic disease. Anticoagulation
is commonly initiated concurrently with chemotherapy, and
retroperitoneal lymph node dissection with/without further
surgical exploration is often required for residual disease.
Renal cell carcinoma frequentlymetastasizes to the lumen
of the IVC, but seminoma can also mimic this picture. Case
reports exist of IVC involvement on initial presentation,
although involvement is more typically found after diagnosis
[5]. In a 20-year retrospective review of testicular cancer
patients at a single institution, the incidence of intraluminal
thrombus at postchemotherapy retroperitoneal lymph node
dissection was found to be 5.8% [6]. The study identified
89 postchemotherapy patients with 98 intraluminal thrombi
(72 IVC, 20 renal vein, and 1 aorta), and active malignancy
was found in approximately 45%. Of the patients with
intraluminal thrombus, one-half eventually required vena
cavectomy for curative treatment.
4. Conclusion
Testicular cancer is a commonmalignancy formales aged 15–
40. Initial presentation involving an IVC tumor thrombus is
rare, especially in the setting of regressed testicular tumor.
Treatment should follow the standard guidelines of testicular
and retroperitoneal imaging, orchiectomy, and chemother-
apy. Pulmonary embolus precautions should be taken, and
patients should be counseled that retroperitoneal lymph node
dissection with vascular reconstruction may be necessary.
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